CSBio CSBio

X
[{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied DNA and Takis Biotech partner on coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Takis Biotech"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied DNA Sciences Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA\u2122 Vaccine Candidates Designed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Takis Biotech"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takis Vaccines Neutralize SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Takis Biotech"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Rottapharm Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.3 million","newsHeadline":"Rottapharm Biotech and Takis Enter an Agreement for the Co-Development of the Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Takis Biotech"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA, Takis Announce Positive Preclinical Results from LineaDNA Vaccine Candidates for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Takis Biotech"},{"orgOrder":0,"company":"ReiThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"After The USA And Australia, The First Pre-Clinical Animal Tests Are Also Carried Out In Italy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"ReiThera"},{"orgOrder":0,"company":"ReiThera","sponsor":"The Ragon Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Vaccine","graph2":"ReiThera"},{"orgOrder":0,"company":"IRBM","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"IRBM"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The collaboration aims to develop a novel HIV vaccine candidate that will be composed of ReiThera’s Gorilla adenoviral vector (GRAd) and HIV T cell epitopes identified by the Ragon Institute.

            Lead Product(s): GRAd-HIV Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: The Ragon Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 22, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Antios will purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) which is being developed for the treatment of HBV.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Antios Therapeutics

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition November 15, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            All animals demonstrated seroconversion to producing IgG against SARS-CoV-2 Spike Protein already by day 14, and significantly enhanced responses by day 38.

            Lead Product(s): LineaDNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Applied DNA Sciences Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 17, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of this collaboration, Rottapharm Biotech will provide Takis with operational support, and with the financial resources needed to complete Phase I/II clinical trials.

            Lead Product(s): COVID-eVax

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Rottapharm Biotech

            Deal Size: Undisclosed Upfront Cash: $3.3 million

            Deal Type: Collaboration June 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Researchers at National Institute of Infectious Diseases found that Takis vaccines after a single vaccination developed antibodies in mice that can block the infection of SARS-CoV-2 on human cells.

            Lead Product(s): DNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The vaccine developed by ReiThera has been obtained from a fragment of the genetic material of the virus and is based on the technology called electroporation.

            Lead Product(s): Covid-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Applied DNA is expected to enter large-scale production of candidates in march; preclinical testing in animals by takis biotech anticipated to begin in calendar Q2 2020.

            Lead Product(s): Linear DNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Applied DNA Sciences Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on polymerase chain reaction (PCR).

            Lead Product(s): Linear DNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Applied DNA Sciences Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 10, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY